Karen S. Lynch - Nov 28, 2021 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
President and CEO, Director
Signature
/s/ Karen S. Lynch
Stock symbol
CVS
Transactions as of
Nov 28, 2021
Transactions value $
-$1,292,354
Form type
4
Date filed
12/1/2021, 03:28 PM
Next filing
Dec 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Tax liability -$1.29M -14.1K -16.97% $91.52 69.1K Nov 28, 2021 Direct F1
holding CVS Common Stock (By Trust) 94.4K Nov 28, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Appreciation Rights 193K Nov 28, 2021 Common Stock 193K $45.91 Direct F2
holding CVS Stock Appreciation Rights 94K Nov 28, 2021 Common Stock 94K $37.91 Direct F3
holding CVS Stock Option 242K Nov 28, 2021 Common Stock 242K $54.19 Direct F4
holding CVS Stock Option 211K Nov 28, 2021 Common Stock 211K $58.34 Direct F5, F6
holding CVS Stock Option 225K Nov 28, 2021 Common Stock 225K $74.30 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock unit award.
F2 Represents unvested Aetna Inc. Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Stock Incentive Plan (the "Aetna Plan") on February 17, 2017 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested in two substantially equal annual installments beginning on February 17, 2019.
F3 Represents unvested SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F4 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F5 The number of shares subject to the option were calculated using a 30-day average price.
F6 Options became exercisable in four equal installments, commencing 4/1/2021.
F7 Option becomes exercisable in four equal installments, commencing 4/1/2022.